Home LiteratureArticle Details
PMID: 18501754 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Surfactant for pediatric acute lung injury.

Pediatric clinics of North America ·Vol. 55 ·No. 3 ·2008-06-00 ·Pages 545-75, ix

Willson DF, Chess PR, Notter RH

Abstract

This article reviews exogenous surfactant therapy and its use in mitigating acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) in infants, children, and adults. Biophysical and animal research documenting surfactant dysfunction in ALI/ARDS is described, and the scientific rationale for treatment with exogenous surfactant is discussed. Major emphasis is placed on reviewing clinical studies of surfactant therapy in pediatric and adult patients who have ALI/ARDS. Particular advantages from surfactant therapy in direct pulmonary forms of these syndromes are described. Also discussed are additional factors affecting the efficacy of exogenous surfactants in ALI/ARDS.

MeSH Terms
Humans Incidence Infant, Newborn Pulmonary Surfactants/metabolism Respiratory Distress Syndrome, Newborn/drug therapy,epidemiology,metabolism Surface-Active Agents/therapeutic use Survival Rate Treatment Outcome United States/epidemiology
Chemicals
Pulmonary Surfactants Surface-Active Agents
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Willson Douglas F
Pediatric ICU and Division of Pediatric Critical Care, University of Virginia Children's Medical Center, UVA Health Sciences System, Box 800386, Charlottesville, VA 22908-0386, USA. [email protected]
Chess Patricia R
Notter Robert H
References (207)
207 references, click to expand
  1. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome.
    Arch Dis Child Fetal Neonatal Ed. 1995 Jan;72(1):F8-13 PMID: 7743295
  2. Aerosolized surfactant improves pulmonary function in endotoxin-induced lung injury.
    Am J Respir Crit Care Med. 1998 Sep;158(3):840-5 PMID: 9731014
  3. Surfactant replacement therapy for meconium aspiration syndrome.
    Pediatrics. 1996 Jan;97(1):48-52 PMID: 8545223
  4. Bovine surfactant therapy for patients with acute respiratory distress syndrome.
    Am J Respir Crit Care Med. 1997 Apr;155(4):1309-15 PMID: 9105072
  5. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis.
    Am J Respir Crit Care Med. 1996 Jul;154(1):57-62 PMID: 8680699
  6. Surface properties, morphology and protein composition of pulmonary surfactant subtypes.
    Biochem J. 1996 Dec 1;320 ( Pt 2):599-605 PMID: 8973573
  7. Surfactant abnormalities in patients with respiratory failure after multiple trauma.
    Am Rev Respir Dis. 1989 Oct;140(4):1033-9 PMID: 2802366
  8. Effect of exogenous surfactant instillation on experimental acute lung injury.
    J Appl Physiol (1985). 1989 Apr;66(4):1846-51 PMID: 2732176
  9. Total extracellular surfactant is increased but abnormal in a rat model of gram-negative bacterial pneumonia.
    Am J Physiol Lung Cell Mol Physiol. 2002 Sep;283(3):L655-63 PMID: 12169586
  10. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity.
    J Appl Physiol (1985). 1987 Oct;63(4):1434-42 PMID: 3693177
  11. Acute lung injury in pediatric intensive care in Australia and New Zealand: a prospective, multicenter, observational study.
    Pediatr Crit Care Med. 2007 Jul;8(4):317-23 PMID: 17545931
  12. Abnormal surfactant composition and activity in severe bronchiolitis.
    Acta Paediatr. 1999 Sep;88(9):942-6 PMID: 10519333
  13. Effect of different surfactants on pulmonary group B streptococcal infection in premature rabbits.
    J Pediatr. 1994 Dec;125(6 Pt 1):939-47 PMID: 7996369
  14. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome.
    Am J Respir Crit Care Med. 1996 Jan;153(1):404-10 PMID: 8542150
  15. Interaction of exogenous and endogenous surfactant: spreading-rate effects.
    J Appl Physiol (1985). 1995 Feb;78(2):750-6 PMID: 7759450
  16. Identification of patients with acute lung injury. Predictors of mortality.
    Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):1818-24 PMID: 8520742
  17. Pulmonary surfactant in health and human lung diseases: state of the art.
    Eur Respir J. 1999 Jun;13(6):1455-76 PMID: 10445627
  18. Evaluation of exogenous surfactant treatment strategies in an adult model of acute lung injury.
    J Appl Physiol (1985). 1996 Apr;80(4):1156-64 PMID: 8926241
  19. Mechanisms of peroxynitrite-induced injury to pulmonary surfactants.
    Am J Physiol. 1993 Dec;265(6 Pt 1):L555-64 PMID: 8279572
  20. Sublethal hyperoxic injury to the alveolar epithelium and the pulmonary surfactant system.
    Exp Lung Res. 1988;14 Suppl:1021-33 PMID: 3208725
  21. P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant.
    Am J Physiol Lung Cell Mol Physiol. 2000 Mar;278(3):L599-609 PMID: 10710533
  22. Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia.
    Infect Immun. 2001 Feb;69(2):758-64 PMID: 11159965
  23. Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome.
    Am J Physiol. 1995 Jul;269(1 Pt 1):L109-18 PMID: 7631805
  24. Epidemiology of acute lung injury.
    Crit Care Med. 2003 Apr;31(4 Suppl):S276-84 PMID: 12682453
  25. Altered surfactant function and metabolism in rabbits with acute lung injury.
    J Appl Physiol (1985). 1990 Dec;69(6):2303-10 PMID: 2077029
  26. Comparative studies on the biophysical activities of the low-molecular-weight hydrophobic proteins purified from bovine pulmonary surfactant.
    Biochim Biophys Acta. 1988 Aug 12;961(3):337-50 PMID: 3401500
  27. Surface properties of sulfur- and ether-linked phosphonolipids with and without purified hydrophobic lung surfactant proteins.
    Chem Phys Lipids. 2005 Oct;137(1-2):77-93 PMID: 16109391
  28. Surfactant protein B and C analogues.
    Mol Genet Metab. 2000 Sep-Oct;71(1-2):342-51 PMID: 11001826
  29. Inhibition of pulmonary surfactant by oleic acid: mechanisms and characteristics.
    J Appl Physiol (1985). 1992 May;72(5):1708-16 PMID: 1601776
  30. Partial liquid ventilation in premature lambs with respiratory distress syndrome: efficacy and compatibility with exogenous surfactant.
    J Pediatr. 1995 Mar;126(3):412-20 PMID: 7869204
  31. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants.
    Am Rev Respir Dis. 1992 Jan;145(1):24-30 PMID: 1731593
  32. Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome.
    Am J Respir Crit Care Med. 1999 Oct;160(4):1188-95 PMID: 10508806
  33. Changes in subphase aggregates in rabbits injured by free fatty acid.
    Am J Respir Crit Care Med. 1994 May;149(5):1099-106 PMID: 8173747
  34. Surface activity of rabbit pulmonary surfactant subfractions at different concentrations in a captive bubble.
    J Appl Physiol (1985). 1994 Aug;77(2):597-605 PMID: 8002505
  35. Incidence of acute lung injury in the United States.
    Crit Care Med. 2003 Jun;31(6):1607-11 PMID: 12794394
  36. Surfactant abnormalities in infants with severe viral bronchiolitis.
    Arch Dis Child. 1996 Aug;75(2):133-6 PMID: 8869194
  37. Synthetic protein analogues in artificial surfactants.
    Acta Paediatr. 1996 Jun;85(6):642-6 PMID: 8816196
  38. Physiologic response and lung distribution of lavage versus bolus Exosurf in piglets with acute lung injury.
    Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1838-43 PMID: 8665043
  39. Phospholipases introduced into the hypophase affect the surfactant film outlining a bubble.
    J Appl Physiol (1985). 1992 Sep;73(3):941-5 PMID: 1400060
  40. Additivity of protein and nonprotein inhibitors of lung surfactant activity.
    Am J Respir Crit Care Med. 1998 Jul;158(1):28-35 PMID: 9655703
  41. Calf's lung surfactant extract in acute hypoxemic respiratory failure in children.
    Crit Care Med. 1996 Aug;24(8):1316-22 PMID: 8706485
  42. The acute respiratory distress syndrome: definitions, severity and clinical outcome. An analysis of 101 clinical investigations.
    Intensive Care Med. 1996 Jun;22(6):519-29 PMID: 8814466
  43. High-frequency jet ventilation and surfactant treatment of newborns with severe respiratory failure.
    Pediatr Pulmonol. 1992 Jun;13(2):108-12 PMID: 1495854
  44. A biophysical mechanism by which plasma proteins inhibit lung surfactant activity.
    Chem Phys Lipids. 1988 Nov;49(1-2):49-55 PMID: 3233711
  45. Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia.
    Anesth Analg. 1991 May;72(5):589-95 PMID: 1850209
  46. Incidence of acute respiratory distress syndrome and its relation to age.
    J Crit Care. 2005 Sep;20(3):274-80 PMID: 16253798
  47. Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent Study Group.
    N Engl J Med. 1996 Sep 12;335(11):761-7 PMID: 8778584
  48. Surfactant subtypes in mice: characterization and quantitation.
    J Appl Physiol (1985). 1989 Jan;66(1):342-9 PMID: 2917940
  49. Lipid mixing is mediated by the hydrophobic surfactant protein SP-B but not by SP-C.
    Biochim Biophys Acta. 1992 Sep 21;1110(1):45-50 PMID: 1390835
  50. A comparison of surfactant delivery with conventional mechanical ventilation and partial liquid ventilation in meconium aspiration injury.
    Respir Med. 2001 Jul;95(7):612-7 PMID: 11453320
  51. The acute respiratory distress syndrome.
    N Engl J Med. 2000 May 4;342(18):1334-49 PMID: 10793167
  52. Experimental aspiration trauma: comparison of steroid treatment versus exogenous natural surfactant.
    Exp Lung Res. 1993 May-Jun;19(3):397-405 PMID: 8319606
  53. Pediatric acute lung injury: prospective evaluation of risk factors associated with mortality.
    Am J Respir Crit Care Med. 2005 May 1;171(9):995-1001 PMID: 15618461
  54. Surfactant and the adult respiratory distress syndrome.
    Am Rev Respir Dis. 1993 Jan;147(1):218-33 PMID: 8420422
  55. Predicting death in pediatric patients with acute respiratory failure. Pediatric Critical Care Study Group. Extracorporeal Life Support Organization.
    Chest. 1995 Sep;108(3):789-97 PMID: 7656635
  56. PRISM III: an updated Pediatric Risk of Mortality score.
    Crit Care Med. 1996 May;24(5):743-52 PMID: 8706448
  57. Spiking Survanta with synthetic surfactant peptides improves oxygenation in surfactant-deficient rats.
    Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):855-61 PMID: 9310004
  58. Content-dependent activity of lung surfactant protein B in mixtures with lipids.
    Am J Physiol Lung Cell Mol Physiol. 2002 Nov;283(5):L897-906 PMID: 12376341
  59. Acute hypoxemic respiratory failure in infants and children: clinical and pathologic characteristics.
    Crit Care Med. 1992 Sep;20(9):1223-34 PMID: 1521437
  60. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys.
    Pediatr Res. 1996 Apr;39(4 Pt 1):715-24 PMID: 8848350
  61. Surfactant therapy in infants and children: three years experience in a pediatric intensive care unit.
    Shock. 2002 Apr;17(4):247-51 PMID: 11954821
  62. Porcine-derived surfactant treatment of severe bronchiolitis.
    Acta Anaesthesiol Scand. 1998 Aug;42(7):805-10 PMID: 9698957
  63. Differential activity and lack of synergy of lung surfactant proteins SP-B and SP-C in interactions with phospholipids.
    J Lipid Res. 1996 Aug;37(8):1749-60 PMID: 8864959
  64. Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza A pneumonia in mice.
    Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):859-63 PMID: 1313214
  65. Surfactant. Evolving issues.
    Clin Perinatol. 1998 Mar;25(1):17-32 PMID: 9523072
  66. Incidence of acute respiratory distress syndrome in German children and adolescents: a population-based study.
    Crit Care Med. 2005 Jan;33(1):209-312 PMID: 15644671
  67. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol.
    J Clin Invest. 1982 Sep;70(3):673-83 PMID: 6896715
  68. Inhibitory effects of oxyradicals on surfactant function: utilizing in vitro Fenton reaction.
    Lung. 1998;176(1):63-72 PMID: 9436178
  69. Clinical risks for development of the acute respiratory distress syndrome.
    Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 1):293-301 PMID: 7842182
  70. Effect of mechanical ventilator weaning protocols on respiratory outcomes in infants and children: a randomized controlled trial.
    JAMA. 2002 Nov 27;288(20):2561-8 PMID: 12444863
  71. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation.
    N Engl J Med. 1991 Mar 28;324(13):865-71 PMID: 2000109
  72. Synthetic surfactant protein analogues.
    Biol Neonate. 1998 Sep;74 Suppl 1:9-14 PMID: 9730586
  73. Incidence and short-term outcome of acute lung injury in mechanically ventilated children.
    Eur Respir J. 2003 Dec;22(6):980-5 PMID: 14680089
  74. Effects of surfactant supplement and end-expiratory pressure in lung-lavaged rabbits.
    J Appl Physiol Respir Environ Exerc Physiol. 1984 Oct;57(4):995-1001 PMID: 6389455
  75. Pulmonary mechanics in ventilated preterm infants with respiratory distress syndrome after exogenous surfactant administration: a comparison between two surfactant preparations.
    Pediatr Pulmonol. 1994 Nov;18(5):273-8 PMID: 7898964
  76. Controversies: synthetic or natural surfactant. The case for natural surfactant.
    J Perinat Med. 1996;24(5):417-26 PMID: 8950721
  77. Dynamic surface activity of a fully synthetic phospholipase-resistant lipid/peptide lung surfactant.
    PLoS One. 2007 Oct 17;2(10):e1039 PMID: 17940603
  78. Surface property changes from interactions of albumin with natural lung surfactant and extracted lung lipids.
    Chem Phys Lipids. 1985 Sep;38(3):287-98 PMID: 3841303
  79. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations.
    Eur Respir J. 1993 Jul;6(7):971-7 PMID: 8370446
  80. Comparison of clinical responses to natural and synthetic surfactants.
    J Perinat Med. 1993;21(5):341-7 PMID: 8126629
  81. Lung surfactant and reactive oxygen-nitrogen species: antimicrobial activity and host-pathogen interactions.
    Am J Physiol Lung Cell Mol Physiol. 2001 Sep;281(3):L517-23 PMID: 11504674
  82. Chemical synthesis and surface properties of an analog of the pulmonary surfactant dipalmitoyl phosphatidylcholine.
    Biochim Biophys Acta. 1977 Aug 24;488(2):235-48 PMID: 578117
  83. Respiratory distress and surfactant inhibition following vagotomy in rabbits.
    J Appl Physiol (1985). 1986 Nov;61(5):1741-8 PMID: 3781984
  84. Effect of surfactant replacement on Pneumocystis carinii pneumonia in rats.
    Intensive Care Med. 1991;17(8):475-8 PMID: 1797892
  85. Multiple mechanisms of lung surfactant inhibition.
    Pediatr Res. 1999 Jul;46(1):85-93 PMID: 10400140
  86. Characterization of lipid insertion into monomolecular layers mediated by lung surfactant proteins SP-B and SP-C.
    Biochemistry. 1991 Nov 12;30(45):10965-71 PMID: 1932022
  87. Surfactant therapy in full-term neonates with severe respiratory failure.
    Pediatrics. 1993 Jul;92(1):135-9 PMID: 8516059
  88. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome.
    Chest. 1994 Jan;105(1):195-202 PMID: 8031347
  89. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant.
    Am J Respir Crit Care Med. 2003 Jun 1;167(11):1562-6 PMID: 12649125
  90. Use of human surfactant low molecular weight apoproteins in the reconstitution of surfactant biologic activity.
    J Clin Invest. 1988 Mar;81(3):826-33 PMID: 3343343
  91. Subfractionation of lung surfactant. Implications for metabolism and surface activity.
    Biochim Biophys Acta. 1983 Jan 7;750(1):18-31 PMID: 6824713
  92. Surfactant treatment for acute respiratory distress syndrome.
    Arch Dis Child. 1999 Mar;80(3):248-52 PMID: 10325705
  93. An expanded definition of the adult respiratory distress syndrome.
    Am Rev Respir Dis. 1988 Sep;138(3):720-3 PMID: 3202424
  94. Surface-area cycling of different surfactant preparations: SP-A and SP-B are essential for large-aggregate integrity.
    Biochem J. 1994 Jun 1;300 ( Pt 2):519-24 PMID: 8002958
  95. Interaction of lipid vesicles with monomolecular layers containing lung surfactant proteins SP-B or SP-C.
    Biochemistry. 1991 Aug 20;30(33):8276-81 PMID: 1868098
  96. Artificial pulmonary surfactant inhibited by proteins.
    J Appl Physiol (1985). 1987 Feb;62(2):429-37 PMID: 3558203
  97. Alterations in bronchoalveolar lavage fluid during ischemia-induced acute hepatic failure in the pig.
    Hepatology. 2003 May;37(5):1130-8 PMID: 12717394
  98. Alveolar hyperoxic injury in rabbits receiving exogenous surfactant.
    J Appl Physiol (1985). 1989 Mar;66(3):1087-92 PMID: 2496084
  99. Surfactant nebulization versus instillation during high frequency ventilation in surfactant-deficient rabbits.
    Pediatr Res. 1998 Nov;44(5):699-704 PMID: 9803451
  100. Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Members of the Mid-Atlantic Pediatric Critical Care Network.
    Crit Care Med. 1999 Jan;27(1):188-95 PMID: 9934915
  101. Synthesis and surface activity of diether-linked phosphoglycerols: potential applications for exogenous lung surfactants.
    Bioorg Med Chem Lett. 2007 Jan 1;17(1):113-7 PMID: 17055273
  102. Adult respiratory distress syndrome in children.
    J Pediatr. 1982 Sep;101(3):352-7 PMID: 7050328
  103. Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lungs.
    Am J Respir Cell Mol Biol. 2007 Oct;37(4):387-94 PMID: 17556674
  104. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure.
    Pediatr Crit Care Med. 2002 Jul;3(3):261-268 PMID: 12780967
  105. Effects of aerosolized artificial surfactant on repeated oleic acid injury in sheep.
    Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):1014-9 PMID: 2327634
  106. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties.
    Eur Respir J. 2002 May;19(5):797-804 PMID: 12030716
  107. Surface activity of a synthetic lung surfactant containing a phospholipase-resistant phosphonolipid analog of dipalmitoyl phosphatidylcholine.
    Am J Physiol Lung Cell Mol Physiol. 2003 Sep;285(3):L550-9 PMID: 12902318
  108. The role of charged amphipathic helices in the structure and function of surfactant protein B.
    J Pept Res. 2005 Dec;66(6):364-74 PMID: 16316452
  109. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Vermont-Oxford Neonatal Network.
    Pediatrics. 1996 Jan;97(1):1-6 PMID: 8545199
  110. Inhibition of pulmonary surfactant function by meconium.
    Am J Obstet Gynecol. 1991 Feb;164(2):477-81 PMID: 1992687
  111. Surfactant replacement in the treatment of sepsis-induced adult respiratory distress syndrome in pigs.
    Crit Care Med. 1996 Jun;24(6):1025-33 PMID: 8681569
  112. Surfactant improves oxygenation in infants and children with pneumonia and acute respiratory distress syndrome.
    Acta Paediatr. 2002;91(11):1174-8 PMID: 12463314
  113. Distribution of exogenous surfactant in rabbits with severe respiratory failure: the effect of volume.
    Pediatr Res. 1993 Aug;34(2):154-8 PMID: 8233717
  114. Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock.
    J Lab Clin Med. 1984 Dec;104(6):873-81 PMID: 6548766
  115. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema.
    Am J Respir Crit Care Med. 1996 Jan;153(1):176-84 PMID: 8542113
  116. Paediatric index of mortality (PIM): a mortality prediction model for children in intensive care.
    Intensive Care Med. 1997 Feb;23(2):201-7 PMID: 9069007
  117. Novel phospholipase-resistant lipid/peptide synthetic lung surfactants.
    Mini Rev Med Chem. 2007 Sep;7(9):932-44 PMID: 17897082
  118. Characteristics of pulmonary surfactant in adult respiratory distress syndrome associated with trauma and shock.
    Am Rev Respir Dis. 1977 Mar;115(3):531-6 PMID: 576571
  119. The use of synthetic peptides in the formation of biophysically and biologically active pulmonary surfactants.
    Pediatr Res. 1991 May;29(5):460-5 PMID: 1896249
  120. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer.
    J Appl Physiol (1985). 1985 Feb;58(2):326-38 PMID: 3838543
  121. Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant.
    Pediatr Res. 1995 Mar;37(3):271-6 PMID: 7784134
  122. Alteration of alveolar surfactant function after exposure to oxidative stress and to oxygenated and native arachidonic acid in vitro.
    Biochim Biophys Acta. 1985 Jun 14;835(1):58-67 PMID: 3924109
  123. Respiratory failure following anti-lung serum: study on mechanisms associated with surfactant system damage.
    Exp Lung Res. 1987;12(2):163-80 PMID: 3569167
  124. Chemical synthesis and surface activity of lung surfactant phospholipid analogs. II. Racemic N-substituted diether phosphonolipids.
    Biochim Biophys Acta. 1991 Jun 19;1084(1):1-12 PMID: 2054372
  125. Improved oxygenation with exogenous surfactant administration in experimental meconium aspiration syndrome.
    Pediatr Pulmonol. 1994 Feb;17(2):75-80 PMID: 8165041
  126. Bronchoalveolar lavage with KL4-surfactant in models of meconium aspiration syndrome.
    Pediatr Res. 1998 Nov;44(5):705-15 PMID: 9803452
  127. Surfactant abnormalities and adult respiratory failure.
    Lung. 1990;168 Suppl:891-902 PMID: 2117209
  128. Ultrasonic and jet aerosolization of phospholipids and the effects on surface activity.
    Pediatr Res. 1983 Sep;17(9):742-7 PMID: 6622110
  129. Gas exchange and lung morphology after surfactant replacement in experimental adult respiratory distress syndrome induced by repeated lung lavage.
    Acta Anaesthesiol Scand. 1986 May;30(4):321-8 PMID: 3090844
  130. Surfactant aerosol treatment of respiratory distress syndrome in the spontaneously breathing premature rabbit.
    Pediatr Res. 1996 Jun;39(6):953-7 PMID: 8725254
  131. A role for phospholipase A2 in ARDS pathogenesis.
    Mol Med Today. 1999 Jun;5(6):244-9 PMID: 10366819
  132. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis.
    Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1251-6 PMID: 11029326
  133. Surfactant replacement attenuates the increase in alveolar permeability in hyperoxia.
    J Appl Physiol (1985). 1989 Aug;67(2):688-93 PMID: 2793671
  134. Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants.
    Am J Physiol. 1992 Mar;262(3 Pt 1):L286-91 PMID: 1550251
  135. Surfactant improves lung function and morphology in newborn rabbits with meconium aspiration.
    Biol Neonate. 1993;63(2):96-104 PMID: 8448260
  136. Surfactant lavage treatment in a model of respiratory distress syndrome.
    Chest. 1999 Jul;116(1 Suppl):85S-86S PMID: 10424605
  137. Inhibition of pulmonary surfactant function by phospholipases.
    J Appl Physiol (1985). 1991 Jul;71(1):317-21 PMID: 1917756
  138. Pulmonary surfactant protein B (SP-B): structure-function relationships.
    Science. 1991 Oct 25;254(5031):566-8 PMID: 1948032
  139. Incidence and outcomes of acute lung injury.
    N Engl J Med. 2005 Oct 20;353(16):1685-93 PMID: 16236739
  140. Hydrophobic surfactant proteins and their analogues.
    Neonatology. 2007;91(4):303-10 PMID: 17575474
  141. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.
    Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):818-24 PMID: 7509706
  142. Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome.
    Crit Care Med. 2005 Apr;33(4):772-9 PMID: 15818104
  143. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group.
    N Engl J Med. 1996 May 30;334(22):1417-21 PMID: 8618579
  144. PEEP is necessary for exogenous surfactant to reduce pulmonary edema in canine aspiration pneumonitis.
    J Appl Physiol (1985). 1992 Aug;73(2):679-86 PMID: 1399997
  145. Effect of recombinant SP-C surfactant in a porcine lavage model of acute lung injury.
    J Appl Physiol (1985). 2000 Feb;88(2):674-81 PMID: 10658037
  146. Protein-phospholipid interactions in pulmonary surfactant. The Parker B. Francis Lectureship.
    Chest. 1994 Mar;105(3 Suppl):57S-62S PMID: 8131614
  147. Surfactant treatment of full-term newborns with respiratory failure.
    Pediatrics. 1991 Jan;87(1):101-7 PMID: 1984603
  148. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group.
    J Pediatr. 1998 Jan;132(1):40-7 PMID: 9469998
  149. Surfactant dysfunction and lung injury due to the E. coli virulence factor hemolysin in a rat pneumonia model.
    Am J Physiol Lung Cell Mol Physiol. 2007 Mar;292(3):L632-43 PMID: 17341765
  150. Bronchoalveolar lavage with a diluted surfactant suspension prior to surfactant instillation improves the effectiveness of surfactant therapy in experimental acute respiratory distress syndrome (ARDS).
    Intensive Care Med. 1998 May;24(5):494-500 PMID: 9660267
  151. The suitability of the Pediatric Index of Mortality (PIM), PIM2, the Pediatric Risk of Mortality (PRISM), and PRISM III for monitoring the quality of pediatric intensive care in Australia and New Zealand.
    Pediatr Crit Care Med. 2004 Sep;5(5):447-54 PMID: 15329160
  152. Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury.
    Eur Respir J. 2003 Jun;21(6):1040-5 PMID: 12797501
  153. Extracellular metabolism of pulmonary surfactant: the role of a new serine protease.
    Annu Rev Physiol. 1995;57:135-50 PMID: 7778861
  154. Metabolism of exogenously administered surfactant in the acutely injured lungs of adult rabbits.
    Am Rev Respir Dis. 1992 Jan;145(1):19-23 PMID: 1731583
  155. Effect of prone positioning on clinical outcomes in children with acute lung injury: a randomized controlled trial.
    JAMA. 2005 Jul 13;294(2):229-37 PMID: 16014597
  156. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network.
    J Pediatr. 1993 Nov;123(5):757-66 PMID: 8229487
  157. Surfactant content in children with inflammatory lung disease.
    Crit Care Med. 1996 Jun;24(6):1062-7 PMID: 8681574
  158. Component-specific surface and physiological activity in bovine-derived lung surfactants.
    Chem Phys Lipids. 2002 Jan;114(1):21-34 PMID: 11841823
  159. Interactions between plasma proteins and pulmonary surfactant: pulsating bubble studies.
    Can J Physiol Pharmacol. 1989 Jun;67(6):663-8 PMID: 2476209
  160. Proteolytic inactivation of dog lung surfactant-associated proteins by neutrophil elastase.
    Biochim Biophys Acta. 1989 Sep 15;992(3):251-7 PMID: 2775786
  161. Surfactant therapy in the USA: trials and current routines.
    Biol Neonate. 1997;71 Suppl 1:1-7 PMID: 9209741
  162. Overview of clinical trials comparing natural and synthetic surfactants.
    Biol Neonate. 1995;67 Suppl 1:32-47 PMID: 7647157
  163. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome.
    J Clin Invest. 1991 Dec;88(6):1976-81 PMID: 1752956
  164. Lysophosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by serum proteins.
    Biochim Biophys Acta. 1991 Oct 15;1086(1):63-71 PMID: 1954245
  165. Pulmonary surfactant subfractions in patients with the acute respiratory distress syndrome.
    Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):1867-71 PMID: 8520748
  166. Surfactant displacement by meconium free fatty acids: an alternative explanation for atelectasis in meconium aspiration syndrome.
    J Pediatr. 1987 May;110(5):765-70 PMID: 3572631
  167. Spreading of exogenous surfactant in an airway.
    J Appl Physiol (1985). 1993 Nov;75(5):2028-39 PMID: 8307856
  168. Treatment with bovine surfactant in severe acute respiratory distress syndrome in children: a randomized multicenter study.
    Intensive Care Med. 2003 Mar;29(3):437-46 PMID: 12589529
  169. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome.
    J Pediatr. 1996 Mar;128(3):396-406 PMID: 8774514
  170. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial.
    JAMA. 2005 Jan 26;293(4):470-6 PMID: 15671432
  171. Is surfactant therapy beneficial in the treatment of the term newborn infant with congenital diaphragmatic hernia?
    J Pediatr. 2004 Sep;145(3):312-6 PMID: 15343181
  172. Lavage administration of dilute surfactants after acute lung injury in neonatal piglets.
    Am J Respir Crit Care Med. 1998 Jul;158(1):12-7 PMID: 9655700
  173. Protein composition of rabbit alveolar surfactant subfractions.
    Biochim Biophys Acta. 1984 Dec 21;791(3):320-32 PMID: 6549142
  174. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.
    Crit Care Med. 1992 Jun;20(6):864-74 PMID: 1597042
  175. Concentration-dependent, temperature-dependent non-Newtonian viscosity of lung surfactant dispersions.
    Chem Phys Lipids. 2001 Jul;112(1):11-9 PMID: 11518568
  176. Exogenous surfactant and positive end-expiratory pressure in the treatment of endotoxin-induced lung injury.
    Crit Care Med. 1998 Aug;26(8):1379-89 PMID: 9710098
  177. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome.
    Pediatrics. 1997 Jul;100(1):39-50 PMID: 9200358
  178. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation.
    J Pediatr. 1993 Feb;122(2):261-8 PMID: 8429445
  179. Alveolar surfactant and adult respiratory distress syndrome. Pathogenetic role and therapeutic prospects.
    Clin Investig. 1993 Mar;71(3):177-90 PMID: 8481620
  180. New approaches to managing congenital diaphragmatic hernia.
    Semin Perinatol. 2004 Jun;28(3):185-98 PMID: 15283098
  181. Pulmonary surfactant subtype metabolism is altered after short-term ozone exposure.
    Toxicol Appl Pharmacol. 1995 Sep;134(1):132-8 PMID: 7676447
  182. Positive end-expiratory pressure during KL4 surfactant instillation enhances intrapulmonary distribution in a simian model of respiratory distress syndrome.
    Pediatr Res. 1995 Aug;38(2):211-7 PMID: 7478818
  183. Oxygenation index predicts outcome in children with acute hypoxemic respiratory failure.
    Am J Respir Crit Care Med. 2005 Jul 15;172(2):206-11 PMID: 15817802
  184. Altered phospholipid composition and aggregate structure of lung surfactant is associated with impaired lung function in young children with respiratory infections.
    Am J Respir Cell Mol Biol. 2002 Dec;27(6):714-21 PMID: 12444031
  185. Exogenous surfactant improves ventilation efficiency and alveolar expansion in rats with meconium aspiration.
    Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):764-70 PMID: 8810617
  186. Bulk shear viscosities of endogenous and exogenous lung surfactants.
    Am J Physiol Lung Cell Mol Physiol. 2002 Feb;282(2):L277-84 PMID: 11792632
  187. Altered fatty acid composition of lung surfactant phospholipids in interstitial lung disease.
    Am J Physiol Lung Cell Mol Physiol. 2002 Nov;283(5):L1079-85 PMID: 12376361
  188. Synthesis and interfacial behavior of sulfur-containing analogs of lung surfactant dipalmitoyl phosphatidylcholine.
    Bioorg Med Chem Lett. 2004 Dec 20;14(24):5983-6 PMID: 15546713
  189. Short-term distribution kinetics of intratracheally administered exogenous lung surfactant.
    Pediatr Res. 1992 May;31(5):445-50 PMID: 1603621
  190. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study.
    J Natl Med Assoc. 1994 Jan;86(1):46-52 PMID: 8151722
  191. Dosing and delivery of a recombinant surfactant in lung-injured adult sheep.
    Am J Respir Crit Care Med. 1999 Mar;159(3):741-7 PMID: 10051245
  192. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics.
    Eur Respir J. 2002 May;19(5):805-10 PMID: 12030717
  193. Protein composition of synthetic surfactant affects gas exchange in surfactant-deficient rats.
    Pediatr Res. 1998 May;43(5):666-73 PMID: 9585014
  194. Hyperoxic lung injury reduces exogenous surfactant clearance in vivo.
    Am J Respir Crit Care Med. 1995 Jun;151(6):1843-7 PMID: 7767528
  195. Surfactant alterations in acute inflammatory lung injury from aspiration of acid and gastric particulates.
    Am J Physiol Lung Cell Mol Physiol. 2005 Apr;288(4):L699-708 PMID: 15757954
  196. Synthetic surfactants to treat neonatal lung disease.
    Mol Med Today. 2000 Mar;6(3):119-24 PMID: 10689315
  197. Effects of rSP-C surfactant on oxygenation and histology in a rat-lung-lavage model of acute lung injury.
    Am J Respir Crit Care Med. 1998 Jul;158(1):270-8 PMID: 9655740
  198. Nebulized vs. instilled exogenous surfactant in an adult lung injury model.
    J Appl Physiol (1985). 1991 Oct;71(4):1270-6 PMID: 1757348
  199. Pneumocystis carinii infection sensitizes lung to radiation-induced injury after syngeneic marrow transplantation: role of CD4+ T cells.
    Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1087-96 PMID: 16399785
  200. Lung lavage and surfactant replacement for hydrochloric acid aspiration in rabbits.
    Acta Anaesthesiol Scand. 1990 Apr;34(3):216-21 PMID: 2111628
  201. Hydrolysis of surfactant phospholipids catalyzed by phospholipase A2 and eosinophil lysophospholipases causes surfactant dysfunction: a mechanism for small airway closure in asthma.
    Chest. 2003 Mar;123(3 Suppl):355S PMID: 12628972
  202. Two hydrophobic low-molecular-mass protein fractions of pulmonary surfactant. Characterization and biophysical activity.
    Eur J Biochem. 1987 Oct 15;168(2):255-62 PMID: 3665923
  203. Surfactant replacement reverse respiratory failure induced by intratracheal endotoxin in rats.
    Crit Care Med. 1995 Jan;23(1):149-56 PMID: 8001366
  204. Lung function in premature lambs and rabbits treated with a recombinant SP-C surfactant.
    Am J Respir Crit Care Med. 1998 Feb;157(2):553-9 PMID: 9476872
  205. Surfactant protein-C in ventilated premature lamb lung.
    Pediatr Res. 1998 Dec;44(6):860-4 PMID: 9853918
  206. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome.
    Pediatrics. 1997 Jul;100(1):31-8 PMID: 9200357
  207. Mitigation of pulmonary hyperoxic injury by administration of exogenous surfactant.
    J Appl Physiol (1985). 1987 Feb;62(2):756-61 PMID: 3558235
Article Info
Journal
Pediatric clinics of North America
Abbr.
Pediatr Clin North Am
ISSN
0031-3955
DOI
10.1016/j.pcl.2008.02.016
Email
[email protected]
Published
2008-06-00
Pages
545-75, ix
Language
English
Region
United States
NLM ID
0401126
PMCID
PMC4275446
Subset
IM
Grants
NHLBI NIH HHS · R01 HL056176 · United States
NHLBI NIH HHS · R01 HL056176-08 · United States
NHLBI NIH HHS · HL-56176 · United States
External Links
PubMed source DOI: 10.1016/j.pcl.2008.02.016 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2